Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 218 451 2974

Review Article - Journal of Medical Oncology and Therapeutics (2018) Volume 3, Issue 1

MHC class II restricted neoepitope vaccine: Promising strategy for immunotherapy.

The discovery of neoantigens has provided a promising target of cancer immunotherapy. Compared with MHC class II neoantigens, more lights shed on MHC class I neoantigens mediated cytotoxic CD8+ T cell responses. However, recent studies demonstrated that cancer vaccines induce both CD4+ T cell and CD8+ T cell immune responses can enhance anticancer efficacy, which provide a rationale for future cancer vaccine development based on MHC calss II neoantigens.

Author(s): Qin Wang, Fangjun Chen, Ju Yang, Baorui Liu

Abstract Full Text PDF